These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 30466755)

  • 1. Is it time to routinely incorporate MRD into practice?
    Ravandi F
    Best Pract Res Clin Haematol; 2018 Dec; 31(4):396-400. PubMed ID: 30466755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hematopoietic cell transplantation as treatment of patients with acute myeloid leukemia with measurable residual disease after consolidation therapy.
    Appelbaum FR
    Best Pract Res Clin Haematol; 2018 Dec; 31(4):405-409. PubMed ID: 30466757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal/Measurable Residual Disease Detection in Acute Leukemias by Multiparameter Flow Cytometry.
    Fuda F; Chen W
    Curr Hematol Malig Rep; 2018 Dec; 13(6):455-466. PubMed ID: 30446941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimal residual disease monitoring in acute myeloid leukemia: Focus on MFC-MRD and treatment guidance for elderly patients.
    Sun Y; Zhu G; Zhong H
    Eur J Haematol; 2024 Jun; 112(6):870-878. PubMed ID: 38342613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal Measurable Residual Disease Testing for Acute Myeloid Leukemia.
    Xiao W; Petrova-Drus K; Roshal M
    Surg Pathol Clin; 2019 Sep; 12(3):671-686. PubMed ID: 31352980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT.
    Nagler A; Baron F; Labopin M; Polge E; Esteve J; Bazarbachi A; Brissot E; Bug G; Ciceri F; Giebel S; Gilleece MH; Gorin NC; Lanza F; Peric Z; Ruggeri A; Sanz J; Savani BN; Schmid C; Shouval R; Spyridonidis A; Versluis J; Mohty M
    Bone Marrow Transplant; 2021 Jan; 56(1):218-224. PubMed ID: 32724200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A mind map for managing minimal residual disease in acute myeloid leukemia.
    Benton CB; Ravandi F
    Clin Adv Hematol Oncol; 2017 Nov; 15(11):859-867. PubMed ID: 29200419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurement of Residual Disease in Acute Myeloid Leukemia.
    Vedula RS; Lindsley RC
    Curr Hematol Malig Rep; 2017 Dec; 12(6):574-581. PubMed ID: 29064024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Widespread use of measurable residual disease in acute myeloid leukemia practice.
    Epstein-Peterson ZD; Devlin SM; Stein EM; Estey E; Tallman MS
    Leuk Res; 2018 Apr; 67():92-98. PubMed ID: 29482173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimal residual disease in acute myelogenous leukemia.
    Cruz NM; Mencia-Trinchant N; Hassane DC; Guzman ML
    Int J Lab Hematol; 2017 May; 39 Suppl 1(Suppl 1):53-60. PubMed ID: 28447422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methods of Detection of Measurable Residual Disease in AML.
    Zhou Y; Wood BL
    Curr Hematol Malig Rep; 2017 Dec; 12(6):557-567. PubMed ID: 29098609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of minimal residual disease in the management of acute myeloid leukemia-a case-based discussion.
    Coltoff A; Houldsworth J; Keyzner A; Renteria AS; Mascarenhas J
    Ann Hematol; 2018 Jul; 97(7):1155-1167. PubMed ID: 29704019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical values of gene alterations as marker of minimal residual disease in non-M3 acute myeloid leukemia.
    Yu T; Chi J; Wang L
    Hematology; 2021 Dec; 26(1):848-859. PubMed ID: 34674615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancing acute myeloid leukemia therapy - monitoring response using residual disease testing as a guide to therapeutic decision-making.
    Tomlinson B; Lazarus HM
    Expert Rev Hematol; 2017 Jun; 10(6):563-574. PubMed ID: 28475434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of RNA- and DNA-based methods for measurable residual disease analysis in NPM1-mutated acute myeloid leukemia.
    Pettersson L; Johansson Alm S; Almstedt A; Chen Y; Orrsjö G; Shah-Barkhordar G; Zhou L; Kotarsky H; Vidovic K; Asp J; Lazarevic V; Saal LH; Fogelstrand L; Ehinger M
    Int J Lab Hematol; 2021 Aug; 43(4):664-674. PubMed ID: 34053184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating measurable residual disease in acute myeloid leukemia.
    Ravandi F; Walter RB; Freeman SD
    Blood Adv; 2018 Jun; 2(11):1356-1366. PubMed ID: 29895626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MRD in AML: it is time to change the definition of remission.
    Ossenkoppele GJ; Schuurhuis GJ
    Best Pract Res Clin Haematol; 2014; 27(3-4):265-71. PubMed ID: 25455276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The emerging role of measurable residual disease detection in AML in morphologic remission.
    Buccisano F; Maurillo L; Schuurhuis GJ; Del Principe MI; Di Veroli A; Gurnari C; Venditti A
    Semin Hematol; 2019 Apr; 56(2):125-130. PubMed ID: 30926088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimal residual disease as a biomarker for outcome prediction and therapy optimization in acute myeloid leukemia.
    Buccisano F; Maurillo L; Del Principe MI; Di Veroli A; De Bellis E; Biagi A; Zizzari A; Rossi V; Rapisarda V; Amadori S; Voso MT; Lo-Coco F; Arcese W; Venditti A
    Expert Rev Hematol; 2018 Apr; 11(4):307-313. PubMed ID: 29495904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of minimal residual disease in acute myeloid leukemia: evaluating utility and challenges.
    Álvarez N; Martín A; Dorado S; Colmenares R; Rufián L; Rodríguez M; Giménez A; Carneros L; Sanchez R; Carreño G; Rapado I; Heredia Y; Martínez-López J; Barrio S; Ayala R
    Front Immunol; 2024; 15():1252258. PubMed ID: 38938565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.